Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreVent-ACaLL
2024-511072-33-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Acalabrutinib + venetoclax with Observation (2 arms). Primary endpoint: Grade >=3 infection-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
acalabrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-511072-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511072-33-00.